Stock search

Ticker or company name

Compare stocks

Market: US

  • REGNRegeneron Pharmaceuticals
  • MRNAModerna
  • VRTXVertex Pharmaceuticals

Add stock

Ticker or company

Summary

REGN
Regeneron Pharmaceuticals
$952,40Down −0,32%
Year: Up +37%
67/100Ratio would watch
Open stock page
MRNA
Moderna
$215,27Down −3,63%
Year: Up +795%
22/100Ratio would not consider buying
Open stock page
VRTX
Vertex Pharmaceuticals
$537,79Down −0,15%
Year: Up +24%
72/100Best scoreRatio would consider buying
Open stock page

Verdict

VRTX has the best score (72). REGN grows revenue the fastest. REGN is the cheapest by forward P/E. REGN has the lowest debt load. VRTX has the highest net margin. MRNA has 7 of 10 checks in the red zone.

Verdict by our methodology based on current metrics. Not an investment recommendation.

Traffic light — 10 checks

CheckREGN5 ✓ 2 — 2 ✕MRNA2 ✓ 0 — 7 ✕VRTX5 ✓ 3 — 1 ✕
P/E vs its history20,5—33,7
P/E vs industry20,5—33,7
Forward P/E13,8n/a—27,2
Revenue growth, YoY+18,6%+13,1%+10,5%
EPS growth, YoY+8,3%—+9,3%
Net margin28,5%−110,5%30,7%
Net debt / EBITDA−1,4—−0,6
Free cash flow$3,83 bn−$1,97 bn$3,20 bn
Share count over a year−1,5%+10,3%−0,9%
Cash runwayn/anot needed0,8 yrsn/anot needed

Metrics

Best WorstNo mark — in between

Metric · betterREGNTTMMRNATTMVRTXTTMIndustry medianTTM
P/E TTM ↓Best: 20,5n/aWorst: 33,742,1
Forward P/E ↓Best: 13,8n/aWorst: 27,218,7
PEG ↓Best: 1,2n/aWorst: 3,04,1
P/S TTM ↓Best: 5,8Worst: 35,810,36,6
EV/EBITDA ↓Best: 18,2Worst: 105,929,628,2
P/FCF ↓Best: 27,2Worst: 101,441,926,0

Price, %

  • REGNn/a
  • MRNAn/a
  • VRTXn/a

Returns

Best WorstNo mark — in between

PeriodREGNMRNAVRTX
1 yearn/an/an/a
3 yearsn/an/an/a
5 yearsn/an/an/a
All timen/an/an/a

“Per year” is the average annual return: 90% growth over 3 years is 23,9% per year, not 30%. “All time” starts at the IPO, so only “per year” compares fairly. Prices adjusted for splits, dividends reinvested.

Analysts and insiders

Best WorstNo mark — in between

REGNMRNAVRTX
Share of “buy”72%Worst: 32%Best: 82%
Beat the forecastBest: 4 of 4Best: 4 of 4Worst: 1 of 4
Average “surprise”+16,8%Best: +43,7%Worst: −1,5%
Insiders over 12 monthssales $57,9 msales $78,9 msales $129 m

Details are on each stock page.